3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA

Start Date : April 22, 2019
End Date : April 25, 2019
Time : 8:00 am to5:00 pm

Phone : 16174554188
Email : info@hansonwade.com

Location :
Hilton Boston Logan Airport, 1 Hotel Dr , Boston, MA, 02128, USA


Get Direction View Large Map


Be at the forefront of the insights from 60+ leading experts as they share their learnings on:


Commercialization challenges, the payers perspective and the investors' criteria for business in the current and future NASH market


The non-invasive diagnostics landscape and regulatory considerations on biomarker adoption for clinical trials


Computational methods and artificial intelligence to increase the efficiency of drug development


Scientific rationale of combinational therapeutics as the necessary treatment strategy for NASH to inform pairing decisions


Identification and recruitment of “high risk” patients needed to optimize clinical success and demonstrate sufficient efficacy


Speakers: Adil Mardinoglu  Professor of Systems Biology  Kings College London, Allison Capone  Global Strategic Marketing for Nonalcoholic Steatohepatitis  Intercept, Anthony Samir  Assistant Professor  Harvard Medical School, Brent Tetri  Director, Division of Gastroenterology and Hepatology; Professor of Internal Medicine  Saint Louis University School of Medicine, Bryan Burkey  Head of Pharmacology  Zafgen, Bryan Fuchs  Assistant in Molecular Biology  Massachusetts General Hospital, Claus Kremoser  Chief Executive Officer  Phenex Pharmaceuticals, Dean Hum  Senior Executive Vice President and Chief Scientific Officer  Genfit, Diane Harbison  Chief Executive Officer  Stratified Medicine Scotland Innovation Centre, David Fraser  Chief Scientific Officer  NorthSea Therapeutics, Éric Lefebvre  Chief Medical Officer  Pliant Therapeutics, Etienne Sokal  Chief Scientific and Medical Officer  Promethera Biosciences, Glenn Rosen  Independent Consultant, Greg Everson  Chief Executive Officer  HepQuant, Greg Tesz  Principal Scientist  Pfizer, H. James Harwood  Adjunct Professor Department of Pathology  Wake Forest University School of Medicine, Isai Peimer  Biotech Analyst  Surveyor Capital, Jagpreet Chhatwal  Assistant Professor  Harvard Medical School, James Conway  Senior Scientist-Translational Bioinformatics  MedImmune, Jelena Mann  Professor of Epigenetics, Fibrosis Research Group  Newcastle University, Jen-Chieh (Jay) Chuang  Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences and Research Scientist  Gilead, Jeff Irelan  Director, Scientific Application  Organovo, Julia Brosnan  Senior Director, External Collaborations and Scientific Alliances  Pfizer, Katie Brown  Vice President, Support and Survivorship Program  Lungevity (NASH Patient), Laura Brattain  Research Scientist, Department of Radiology  Massachusetts General Hospital, Laurent Fischer  Senior Vice President  Head Liver Therapeutic Area Allergan, Liat Hayardeny  Chief Scientific Officer  Galmed Pharmaceuticals, Linda Morrow  Vice President and Chief Medical Officer  ProSciento, Maria-Chiara Magnone  Vice President, Metabolic Complications  Janssen Research and Development, Marko Korenjak  Vice President  European Liver Patients Association, Manu Chakravarthy  Chief Medical Officer and Senior Vice President  Axcella Health, Matthews Bradley  Founder, Chairman, President and Chief Technical Officer  SAJE Pharma, Min Lu  Director, Head of Fibrosis  Morphic Therapeutics, Naim Alkhouri  Director of the Metabolic Health Center  Texas Liver Institute, Nikolai Naoumov  Executive Director, Hepatology Sciences and Innovation  Novartis, Patrick Horn  Chief Medical Officer  Albireo Pharmaceuticals, Pascal Prigent  Executive Vice President, Commercial  Genfit, Peter Guzzo  Cofounder and Chief Executive Officer  ConSynance Therapeutics, Peter Caravan  Director of the Institute for Innovation in Imaging  Massachusetts General Hospital, Peter Traber  Partner  Alacrita Consulting, Pietro Scalfaro  Chief Medical Officer  Enyo Pharma, Pnina Fishman  Chief Executive Officer  CanFite BioPharma, Rebecca Taub  Chief Medical Officer, Executive Vice President Research and Development  Madrigal Pharmaceuticals, Richard Lee  Director  Ionis Pharmaceuticals, Richard Torstenson  Independent Regulatory  Advisor, Ritesh Shah  Commercial Development Lead, Internal Medicine  Pfizer, Robert Arch  Executive Director; Head, Liver Disease Program  Novartis Institute for BioMedical Research, Roberto Calle  Executive Director, Internal Medicine Research Unit  Pfizer, Richard Marshall  Chief Medical Officer  Galecto Biotech, Saswata Talukdar  Director – CardioMetabolic Discovery  Merck, Saurabh Gupta  Director – Translational Research and Early Clinical  Takeda, Stephen Previs  Director  Merck, Suneil Hosmane  Executive Vice President- Strategic Development  Genfit, Star Seyedkazemi  Associate Vice President in Clinical Development  Allergan, Wayne Eskridge  Chief Executive Officer  Fatty Liver Foundation, Weilin Xie  Senior Principal Scientist  Celgene, Yury Popov  Assistant Professor of Medicine  Harvard Medical School

Registration Info

Register Now

Admission :

Gold Pass: Full Access (Conference Days + Seminar Day and Discussion Day): USD 4597.0

Silver Pass: Conference + Seminar Day: USD 3898.0

Silver Pass: Conference + Discussion Day (2 Workshops): USD 3898.0

Bronze Pass: Conference Only: USD 2899.0

Bronze Pass: Seminar Day Only: USD 1399.0

Bronze Pass: Discussion Day Only (2 Workshops): USD 1399.0

Contact the Organizer

Organized by

Organized by LoveEvvnt1

Hanson Wade

Email: info@hansonwade.com

Event Categories: Health & Nutrition.

Your Review

You must be logged in to post a comment.